Insilico Medicine Completes $60 Million Funding; Will Build Robotic Drug Discovery Lab
publication date: Jun 6, 2022
Insilico Medicine, a Hong Kong AI-based company, completed a $60 million Series D financing. The company said it will allocate part of the funds to build a fully automated, AI-driven robotic drug discovery laboratory and a fully robotic biological data factory, which will complement its large library of curated data assets. Insilico partners with other biopharma companies, using its AI discovery technology to discover drugs more quickly and at lower cost than traditional methods. Last week, it announced China approval to start trials of sn idiopathic pulmonary fibrosis therapy for its own portfolio. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.